Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street’s estimates seem disconnected from reality and some better opportunities to consider.

Sanmina (SANM)

Consensus Price Target: $190 (27.2% implied return)

Founded in 1980, Sanmina (NASDAQ: SANM) is an electronics manufacturing services company offering end-to-end solutions for various industries.

Why Do We Think Twice About SANM?

1. Annual sales declines of 4.6% for the past two years show its products and services struggled to connect with the market during this cycle
2. Competitive supply chain dynamics and steep production costs are reflected in its low gross margin of 8.3%
3. Earnings per share have contracted by 1.2% annually over the last two years, a headwind for returns as stock prices often echo long-term EPS performance

Sanmina’s stock price of $149.32 implies a valuation ratio of 15.9x forward P/E. Read our free research report to see why you should think twice about including SANM in your portfolio.

Orion (ORN)

Consensus Price Target: $12.17 (18.2% implied return)

Established in 1994, Orion (NYSE: ORN) provides construction services for marine infrastructure and industrial projects.

Why Do We Pass on ORN?

1. Backlog has dropped by 1.7% on average over the past two years, suggesting it’s losing orders as competition picks up
2. Issuance of new shares over the last five years caused its earnings per share to fall by 3.8% annually while its revenue grew
3. Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of -0.7% for the last five years

At $10.29 per share, Orion trades at 39.7x forward P/E. If you’re considering ORN for your portfolio, see our FREE research report to learn more.

Evolent Health (EVH)

Consensus Price Target: $10.11 (143% implied return)

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Why Does EVH Worry Us?

1. 7.1% annual revenue growth over the last two years was slower than its healthcare peers
2. Push for growth has led to negative returns on capital, signaling value destruction, and its shrinking returns suggest its past profit sources are losing steam
3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders

Evolent Health is trading at $4.17 per share, or 17.4x forward P/E. Dive into our free research report to see why there are better opportunities than EVH.

Stocks We Like More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.